10-K: Terns Pharmaceuticals Outlines Capital Structure and Pipeline Progress in Annual Filing

Terns Pharmaceuticals' 10-K filing details its capital stock, registration rights, and progress in developing treatments for CML and obesity, with cash runway into 2026.

Summary

• Terns Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing small-molecule product candidates for oncology and obesity.
• The company's authorized capital stock consists of 150,000,000 shares of common stock and 10,000,000 shares of preferred stock, both with a par value of $0.0001 per share.
• Holders of common stock are entitled to one vote per share and do not have cumulative voting rights.
• Certain stockholders have registration rights, which will terminate when their shares can be sold under Rule 144 or upon a deemed liquidation event.
• The company is developing TERN-701 for CML, TERN-601 for obesity, and TERN-501 for metabolic diseases, with ongoing discovery efforts for the TERN-800 series.
• TERN-701 is an allosteric BCR-ABL TKI, with a Phase 1 trial (CARDINAL) expected to have interim data in the second half of 2024.
• TERN-601 is an oral GLP-1R agonist, with a Phase 1 trial initiated in the fourth quarter of 2023 and top-line data expected in the second half of 2024.
• TERN-501 is a THRagonist, with positive Phase 2a data in MASH, but the company is limiting spend in this indication.
• The company believes its existing cash and cash equivalents will be sufficient to fund operations into 2026 and generate key clinical data readouts.
• The company relies on third-party contract manufacturers for drug supplies and third parties to conduct clinical trials.

Sentiment

Score: 5

Explanation: The document presents a balanced view, highlighting both the potential of the company's pipeline and the risks associated with its development stage. While there are positive aspects, the company's reliance on external parties and the need for future funding temper the overall sentiment.

Positives

• The company has a diversified pipeline with multiple drug candidates in development.
• TERN-701 has received Orphan Drug Designation, which may provide regulatory and commercial benefits.
• The company has a cash runway into 2026, providing financial stability for ongoing development programs.
• The company is exploring both agonist and antagonist approaches for GIPR modulation, which may lead to novel combination therapies.
• The company has a proprietary 3D QSAR model for GLP-1 receptor agonist discovery.

Negatives

• The company has a limited operating history and has incurred significant losses since inception.
• The company is heavily dependent on the successful development, regulatory approval, and commercialization of its product candidates.
• Clinical drug development is a lengthy and expensive process with uncertain timelines and outcomes.
• The company relies completely on third parties for manufacturing and clinical trials.
• The company faces significant competition in the biotechnology industry.

Risks

• The company will require substantial additional financing to achieve its goals.
• Clinical trial results may not be predictive of future trial results.
• The company faces significant competition from other pharmaceutical and biotechnology companies.
• The company relies on third parties for manufacturing and clinical trials, which could lead to delays or failures.
• The company's product candidates could be alleged to infringe on third-party patent rights.
• Adverse changes in the geopolitical relationship between the United States and China could have an adverse effect on business conditions.
• The company's operating results may fluctuate significantly, making future results difficult to predict.
• The company may fail to attract and retain senior management and key scientific personnel.
• The company may be subject to data protection, privacy and security laws, regulations, standards and other requirements.

Future Outlook

The company expects its existing capital resources will fund planned operating expenses into 2026 and generate key clinical data readouts from lead programs. The company also expects to continue to incur losses for the foreseeable future.

Management Comments

• The company believes that its existing cash and cash equivalents will be sufficient to fund its planned operating expenses and capital expenditure requirements into 2026 and be sufficient to generate at least two key clinical data readouts from our lead programs in chronic myeloid leukemia (CML) and obesity.

Industry Context

The document highlights the competitive landscape in the biotechnology industry, particularly in CML and obesity, where numerous companies are developing treatments. The company is positioning itself with novel approaches, such as allosteric TKIs for CML and oral GLP-1 agonists for obesity.

Comparison to Industry Standards

• The document compares Terns' allosteric TKI, TERN-701, to asciminib, the first approved allosteric TKI, noting similar potency against native BCR-ABL and common mutations.
• The document compares Terns' oral GLP-1 agonist, TERN-601, to other oral GLP-1 agonists in development, such as danuglipron, orforglipron, GSBR-1290, and RGT-075, noting a range of weight loss between 3% to 5% placebo-adjusted over a 28-day period.
• The document compares Terns' THRagonist, TERN-501, to other THRagonists in development, noting its high liver distribution and selectivity for THRover THRactivation.
• The document references clinical trial results of semaglutide and tirzepatide for weight loss, setting a benchmark for the obesity market.
• The document references the ASC4FIRST trial of asciminib against investigator-selected TKIs in newly diagnosed CML patients, setting a benchmark for the CML market.

Management Changes

Stakeholder Impact

• Shareholders face risks related to potential dilution and volatility in stock price.
• Employees may be affected by changes in management and potential restructuring.
• Patients may benefit from the development of new treatments for CML and obesity.
• Suppliers and contract manufacturers are key partners in the company's operations.

Next Steps

• The company expects interim data from the CARDINAL trial for TERN-701 in the second half of 2024.
• The company expects top-line data, including 28-day body weight loss, from the Phase 1 trial for TERN-601 in the second half of 2024.
• The company continues to evaluate opportunities for TERN-501 in metabolic diseases.
• The company is engaging in discovery for its lead series of GIPR modulators.

Key Dates

Keywords

Terns Pharmaceuticals, clinical-stage, biopharmaceutical, oncology, obesity, TERN-701, TERN-601, TERN-501, GIPR modulators, GLP-1R agonist, THRagonist, BCR-ABL TKI, MASH, Orphan Drug Designation, clinical trials, drug development, capital stock, registration rights